-
Posted by
Two Blokes Jul 8 -
Filed in
Stock
-
6 views
Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is its next catalyst in the short term. Since Nimacimab can also help with GLP-1 non-responders or as a maintenance therapy, it shows an added potential as a combo therapy.
